Abivax - ABX464-202, A phase 2b, multicenter, double-blind, placebocontrolled, study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of obefazimod in subjects with moderately to severely active Crohn’s disease (Pro00076408)
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Translational Research -
Location
-
Principal Investigator
Jennifer Seminerio-Diehl -
Sponsor
Abivax